Atlas Trials

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

Clinical trial NCT05653323 · COMPLETED

Trial details

NCT number
NCT05653323
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Pain
Start date
2022-12-14
Primary completion
2023-09-12
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.